Provectus Pharmaceuticals, Inc. (PVCT) Receives Orphan Drug Designation from FDA
Provectus Pharmaceuticals, Inc. announced yesterday that they have received orphan drug designation by the U.S. Food and Drug Administration (FDA) for Rose Bengal, the active ingredient in the Company's novel oncology drug PV-10, for the treatment of hepatocellular carcinoma (HCC). HCC is the most common form of primary liver cancer. Provectus completed patient accrual and treatment of all subjects in their Phase 1 clinical trial of PV-10 for liver cancer in January 2011. Currently the Company is designing a Phase 2 study. PV-10 is a proprietary, injectable formulation of Rose Bengal, a compound that has been in use for more…